Australia's most trusted
source of pharma news
Monday, 02 March 2026
Posted 2 March 2026 AM
Ten companies have won March PBS listings, with some even securing subsidy for more than one drug.
Roche’s Columvi has made its debut on the scheme after securing the PBAC’s recommendation in July 2025 for use in combination with gemcitabine and oxaliplatin for patients with relapsed or refractory diffuse large B-cell lymphoma who have received one or more lines of systemic therapy and are unable to receive autologous stem cell transplant or CAR-T cell therapy.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.